Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
DUBLIN, Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, ...
More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...
The company launched its CoreValve Evolut Pro device in Europe for patients in the intermediate, high, and extreme risk category for open surgery. Amanda Pedersen Transcatheter aortic valve ...
The potential is high for TAVR adoption in emerging markets, according to Venkat Rajan, an analyst at Frost & Sullivan. “It is, however, coming in at a higher price point than traditional valves,” he ...
Medtronic plc and Tempus AI Inc. launched the ALERT study to better understand and address the racial, ethnic, gender and geographic disparities associated with guideline-recommended treatments for ...
WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback